Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).

Endometrial Serous Adenocarcinoma

Stage I Uterine Corpus Cancer

Stage II Uterine Corpus Cancer

Stage III Uterine Corpus Cancer

Stage IV Uterine Corpus Cancer

Diagnostic Laboratory Biomarker Analysis

Immunohistochemistry Staining Method

Medical Chart Review

Microarray Analysis

Study of Socioeconomic and Demographic Variables

Western Blotting

Gynecologic Oncology Group

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma

Kaplan-Meier survival curves for the overall survival (OS) endpoint will be generated separately for the three SNCG expression groups and globally compared using a log-rank test.

Cox proportional hazards models with dummy variable coding of the SNCG expression groups will be used to estimate hazard ratios, with tests of interaction with time and log-log plots used to evaluate the proportional hazards assumption. Sensitivity of the estimated hazard ratios to adjustment for other variables will be explored in the analyses for the Secondary Objectives.

Median survival times and 95% confidence intervals will be estimated from the Kaplan-Meier curves using Greenwood's formula for variance estimation.

National Cancer Institute (NCI)

FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration

Ovarian Cancer

placebo

alendronate/cholecalciferol

BC Cancer Agency

Bone Health in Gynecologic Cancers-does FOSAVANCE Help?

The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies.

Jessica McAlpine, MD

British Columbia Cancer Agency

uterine neoplasms

phosphatase

uterine neoplasms/phosphatase

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

Bone Health in Gynecologic Cancers-does FOSAVANCE Help?

The most complete medicinal herbs database backed by science